Cas No.: | 2114365-78-3 |
Chemical Name: | 5-[(5E)-5-[[5-methyl-3-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]furan-2-carboxylic acid |
SMILES: | O1C(C2C(=O)/C(=N/NC3=C(C)NN(C4=CC=C5C(=C4)CCCC5)C3=O)/C=CC=2)=CC=C1C(O)=O |
Formula: | C25H22N4O5 |
M.Wt: | 458.474 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Hetrombopag is a potent, selective, orally-active Thrombopoietin (TPO) receptor agonist; specifically stimulates proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways; specifically enhances the viability and promoted the growth of 32D-MPL cells in hollow fibres implanted in nude mice, exhibiting much higher potency than eltrombopag in vivo. |